Sign in

    Anshul Dhankher

    Research Analyst at LifeSci Capital

    Anshul Dhankher is an Equity Research Analyst at LifeSci Capital, specializing in coverage of biopharmaceutical and emerging life sciences companies, including firms such as Perspective Therapeutics and Aura Biosciences. He has issued 15 stock ratings with a coverage focus on US markets, holding a strong bias toward Buy ratings and notable recommendations like a Buy on Aura Biosciences which yielded a return of +38.5%. Dhankher began his professional career in operations at AbbVie before transitioning to equity research, bringing both corporate and analytical perspectives when he joined LifeSci Capital. Holding a PhD and other professional credentials, he is active in fundamental research and regularly participates in earnings calls and sector analysis.

    Anshul Dhankher's questions to Rain Enhancement Technologies Holdco (RAIN) leadership

    Anshul Dhankher's questions to Rain Enhancement Technologies Holdco (RAIN) leadership • Q2 2023

    Question

    Anshul Dhankher of LifeSci Capital questioned whether Rain Oncology is targeting a specific 'sweet spot' in terms of development stage or deal structure for potential in-licensing opportunities.

    Answer

    CEO Avanish Vellanki responded that the company's primary focus is on clinical-stage assets to leverage the demonstrated expertise of its clinical organization, but he did not provide further specifics on deal structures or other criteria.

    Ask Fintool Equity Research AI